J. Goldman & Co’s GSK GSK Stock Holding History

J. Goldman & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-150,000	Closed	-$5.78M	–	516
2024 Q2	$5.78M	Buy	+150,000	New	+$6.31M	0.16%	165

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

J. Goldman & Co's GSK Position: Q3 2024 in Review

J. Goldman & Co sold out of GSK (GSK) in Q3 2024, closing a stake of 7,473 shares — an estimated $288K sold.

J. Goldman & Co first reported a position in GSK in Q1 2023 and held it in 2 quarters. The position peaked at $3.85M in Q1 2023. 899 funds tracked by Wall St. Rank hold GSK as of Q3 2024.

J. Goldman & Co reported no remaining GSK position as of Q3 2024 after selling out during the quarter.
J. Goldman & Co sold 7,473 GSK shares in Q3 2024, an estimated $288K.
J. Goldman & Co first reported a position in GSK in Q1 2023 and held it in 2 quarters.
J. Goldman & Co's GSK position peaked at $3.85M in Q1 2023.
899 funds tracked by Wall St. Rank held GSK as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.